Age is an independent prognostic factor in rhabdomyosarcoma: A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group
Age is an independent prognostic factor in rhabdomyosarcoma: A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group
复制标题
DOI：
10.1002/pbc.10441
复制
发表时间：
2004-01-01
影响因子：
3.2
通讯作者：
Crist, W
中科院分区：
文献类型：
--
作者：
Joshi, D;Anderson, JR;Crist, W
背景。尽管诊断时年龄< 1 岁与横纹肌肉瘤 (RMS) 的预后较差相关，但诊断时年龄与临床表现和结果的关系尚未得到仔细评估。我们回顾了最近组间横纹肌肉瘤研究委员会（后来称为小组，IRSG）试验的数据，以检验这种关系，以便更准确地估计预后并进一步完善治疗。程序。我们使用 IRS-III、-IV Pilot 和 -IV (198397，N=2,343) 的数据来研究接受当代治疗的一大群患者中患者年龄与临床特征和预后的关系。结果。我们发现，在调整重要的预后因素后，年龄是治疗失败的独立风险因素，并且可以根据年龄将患者分为三个失败风险类别（即<1岁；1-9岁；>10岁）。与 1-9 岁儿童相比，婴儿和青少年更有可能出现不良特征，包括肺泡或未分化肿瘤以及晚期组和分期，并且无失败生存率 (FFS) 也显着较差（53% 和 51% vs. 72%，P < 0.001）。尽管不同年龄类别之间的 FFS 存在差异，但没有证据表明年龄会影响这三个类别的结果。结论。由于年龄与调整已知风险因素后的结果独立相关，因此其他因素（可能包括患者对方案指定治疗的耐受性）可能解释了这种关系。 (c) 2003 Wiley-Liss, Inc.
Background. Although age < 1 year at diagnosis has been associated with a worse prognosis in rhabdomyosarcoma (RMS), the relationship of age at diagnosis to clinical presentation and outcome has not been evaluated carefully. We reviewed data from recent Intergroup Rhabdomyosarcoma Study Committee (later called Group, IRSG) trials to examine this relationship in order to estimate prognosis more accurately and further refine treatment. Procedure. We used data from IRS-III, -IV Pilot, and -IV (198397, N=2,343) to study the relationship of patient age with clinical features and prognosis in a large cohort of patients treated with contemporary therapy. Results. We showed that, after adjusting for important prognostic factors, age was an independent risk factor for treatment failure and patients could be classified into three failure-risk categories based on age (i.e., < 1 year; 1-9 years; > 10 years). Infants and adolescents were more likely to have unfavorable features, including alveolar or undifferentiated tumors and advanced Group and Stage, and also had significantly poorer failure-free survival (FFS) than did children aged 1-9 (53 and 51% vs. 72%, P < 0.001). Although there was a difference in FFS among age categories, there was no evidence that age influences outcome within the three categories. Conclusions. Since age relates independently to outcome after adjustment for known risk factors, it is likely that other factors, including perhaps patients' tolerance of protocol-specified therapy, explain this relationship. (c) 2003 Wiley-Liss, Inc.